{
    "organizations": [],
    "uuid": "89dfffbed53730745bc41a4a07c18b34a2126702",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-fy-net-loss/brief-mithra-pharmaceuticals-fy-net-loss-at-35-0-million-euros-idUSFWN1QJ1GR",
    "ord_in_thread": 0,
    "title": "BRIEF-Mithra Pharmaceuticals FY Net Loss At 35.0 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* CASH AT DECEMBER 31 2017 WAS EUR 36.2‍​ MILLION VERSUS EUR 45.7 MILLION YEAR AGO\n* FY REVENUE EUR 46.3 MILLION VERSUS EUR 22.5 MILLION YEAR AGO\n* FY REBITDA LOSS EUR 18.1 MILLION VERSUS LOSS OF EUR 34.9 MILLION YEAR AGO\n* FY NET LOSS STABLE AT EUR 35.0 MILLION * TOWARDS END OF Q1/EARLY Q2, TOP-LINE PHASE II DOSE-FINDING RESULTS FOR DONESTA ARE EXPECTED\n* RESULTS OF THE FIRST PIVOTAL ESTELLE STUDY IN THE EU & RUSSIA TO BE AVAILABLE IN Q3 2018\n* RESULTS OF ESTELLE STUDY IN US/CANADA PHASE III RESULTS TO BE PUBLISHED IN Q1 2019\n* EUROPEAN APPROVAL CAN ALREADY BE EXPECTED IN Q2/Q3 2018 FOR MYRING\n* FOR MYRING MAYNE PHARMA MAKING SIGNIFICANT PROGRESS FOR THE US APPROVAL AND LAUNCH, EXPECTED IN H1 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-02T15:43:00.000+02:00",
    "crawled": "2018-03-03T17:25:34.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "mithra",
        "pharmaceutical",
        "sa",
        "cash",
        "december",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "rebitda",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "net",
        "loss",
        "stable",
        "eur",
        "million",
        "towards",
        "end",
        "q2",
        "phase",
        "ii",
        "result",
        "donesta",
        "expected",
        "result",
        "first",
        "pivotal",
        "estelle",
        "study",
        "eu",
        "russia",
        "available",
        "q3",
        "result",
        "estelle",
        "study",
        "phase",
        "iii",
        "result",
        "published",
        "q1",
        "european",
        "approval",
        "already",
        "expected",
        "myring",
        "myring",
        "mayne",
        "pharma",
        "making",
        "significant",
        "progress",
        "u",
        "approval",
        "launch",
        "expected",
        "h1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}